Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) Equity Average (2016 - 2025)

Wave Life Sciences' Equity Average history spans 11 years, with the latest figure at $321.5 million for Q4 2025.

  • For Q4 2025, Equity Average rose 83.08% year-over-year to $321.5 million; the TTM value through Dec 2025 reached $321.5 million, up 83.08%, while the annual FY2025 figure was $363.9 million, 192.15% up from the prior year.
  • Equity Average reached $321.5 million in Q4 2025 per WVE's latest filing, up from $131.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $321.5 million in Q4 2025 to a low of -$46.1 million in Q3 2023.
  • Average Equity Average over 5 years is $57.0 million, with a median of $28.5 million recorded in 2021.
  • Peak YoY movement for Equity Average: tumbled 448.9% in 2023, then soared 41122.78% in 2024.
  • A 5-year view of Equity Average shows it stood at $31.2 million in 2021, then plummeted by 179.5% to -$24.8 million in 2022, then soared by 98.27% to -$428000.0 in 2023, then skyrocketed by 41122.78% to $175.6 million in 2024, then surged by 83.08% to $321.5 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Equity Average are $321.5 million (Q4 2025), $131.9 million (Q3 2025), and $155.5 million (Q2 2025).